Summary & Overview
HCPCS Level II M1229: Referral for HCV Viremia to HCV Clinician
HCPCS Level II code M1229 documents a timely referral pathway: patients with a reactive HCV antibody and a subsequent positive HCV viral test are referred to an HCV-treating clinician within one month. This code captures an important care coordination step in the HCV care cascade, emphasizing rapid linkage to evaluation and potential antiviral treatment — a critical measure for reducing transmission and improving patient outcomes nationally. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise review of what the code represents, its clinical context within HCV screening and linkage-to-care workflows, and why capturing timely referral matters for quality measurement and payment. The publication summarizes service expectations and typical sites of service, presents payer coverage considerations and common modifiers used in billing, and outlines areas where data were not provided. This resource is intended for health plan analysts, billing professionals, clinic managers, and policy staff seeking a clear, national-level briefing on the purpose and operational use of M1229 in HCV care coordination.
Billing Code Overview
HCPCS Level II code M1229 describes referral of a patient with a reactive hepatitis C virus (HCV) antibody test who has a follow-up HCV viral test detecting HCV viremia, to a clinician who treats HCV infection within 1 month of the reactive antibody test. The service type is a timely referral for HCV treatment evaluation and linkage to care. The typical site of service is outpatient clinical care settings where diagnostic testing and referrals are managed, such as primary care clinics, infectious disease or hepatology clinics, and community health centers.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient presents to a primary care clinic after routine screening with a reactive hepatitis C virus (HCV) antibody test. A reflex or follow-up HCV RNA (viral) test returns positive, confirming active HCV viremia. Within 30 days of the reactive antibody result, the patient is referred to a clinician who treats HCV infection for staging, treatment discussion, and initiation of direct-acting antiviral therapy if appropriate. Typical workflow: initial screening and antibody test performed in primary care or community clinic; positive antibody triggers order for HCV RNA testing; once RNA detected, case is triaged and a referral is placed to an HCV-treating clinician (infectious disease specialist, hepatologist, gastroenterologist, or primary care clinician with HCV treatment capability). The referral appointment commonly occurs in outpatient specialty clinics, community health centers, or telehealth visits. Relevant activities at the referral visit include confirmation of viral status, baseline laboratory assessment (HCV genotype if indicated, liver function tests, fibrosis assessment), medication reconciliation, insurance prior authorization initiation, and counseling about treatment timeline and monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when additional work beyond usual is documented at the referral visit (e.g., complex medical decision-making for comorbid conditions). |